Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T15:36:32.182Z.
Calculation as of: 2026-10-06T15:36:32.182Z.
Quote observation: 2026-10-06T15:34:55.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 869772d5b15fe2f366f7470de3318cdd420f1d22994776f46b79eb6f67ec6a89
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Eupraxia Pharmaceuticals Inc.
Market Cap
$267.17M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$267.82M
Operating Cash Flow Yield
N/A
TTM Avg
17.72%
3Y Avg
21.01%
5Y Avg
14.11%
Market Cap
$264.62M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$263.39M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$271.23M
Operating Cash Flow Yield
N/A
TTM Avg
2.42%
3Y Avg
2.42%
5Y Avg
2.42%
Market Cap
$262.11M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$260.03M
Operating Cash Flow Yield
N/A
TTM Avg
21.89%
3Y Avg
21.13%
5Y Avg
21.13%
Market Cap
$258.56M
Operating Cash Flow Yield
2.31%
TTM Avg
4.24%
3Y Avg
3.35%
5Y Avg
2.66%
Market Cap
$256.22M
Operating Cash Flow Yield
N/A
TTM Avg
3.96%
3Y Avg
3.96%
5Y Avg
3.96%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Inc. (EPRX) | $267.17M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $267.82M | N/A | 17.72% | 21.01% | 14.11% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $264.62M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.39M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $271.23M | N/A | 2.42% | 2.42% | 2.42% |
| Palisade Bio, Inc. (PALI)vs › | $262.11M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $260.03M | N/A | 21.89% | 21.13% | 21.13% |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.56M | 2.31% | 4.24% | 3.35% | 2.66% |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | N/A | 3.96% | 3.96% | 3.96% |
| Fate Therapeutics, Inc. (FATE)vs › | $279.83M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
